CTRI/2018/01/011061尚未招募4 期
Multicentric Phase IV randomized open label controlled trial to assess effectiveness, safety and acceptability of Polyethylene Glycol 3350 versus Lactulose for treatment of functional constipation in children aged 2 years to 12 years.
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects aged 2 to 12 years of either sex presenting to the outpatient department of the hospital with a clinical diagnosis of functional constipation and fecal incontinence according to the Rome IV criteria, at least 2 of the following:
- •1. 2 or fewer defecations /week.
- •2. History of excessive stool retention
- •3. History of painful or hard bowel movements.
- •4. Presence of a large faecal mass in the rectum
- •5. History of a large diameter stool
- •2.Parent of the subjects must give written informed consent for study participation.
- •3.Parent of the subjects must be willing to maintain subject diary and follow all instructions as per the study protocol.
- •4.If patient has already consumed any laxative for the current episode, then a wash-out period of about 2 weeks to be given before administering study medication.
排除标准
- •1.Subjects with intestinal pseudo obstruction.
- •2.Subjects who are debilitated or seriously ill or immunocompromised.
- •3.Subjects with coexisting features of acute systemic disease like septicemia, meningitis, pneumonia etc.
- •4.Patients with symptoms or suspicion of an organic lesion of the digestive tract, or with undiagnosed abdominal pain or rectal bleeding or other GI disorder especially ulcerative colitis, Crohnâ??s disease, history of carcinomas of the bowel, malabsorption syndrome, intolerance to certain food types (lactose).
- •5.Subjects with hypersensitivity to any ingredient in the formulation.
- •6.Subjects with history of surgery involving the colon or anus.
- •7.Participation in any clinical trial in the last 3 months prior to screening.
- •8.Presence of any other medical or surgical condition which as per the judgment of the principal investigator is not conducive for trial participation.
研究者
相似试验
已完成
4 期
An open label, multicentre, randomized phase IV clinical trial to evaluate the safety and efficacy of MaxioCel compared with Aquacel Extra for the management of exuding chronic wounds.CTRI/2022/04/041745Axio Biosolutions Pvt Ltd
已完成
4 期
An Observational Post Marketing study to check the safety and tolerance of Alerfix Total in patients with AsthmaCTRI/2017/09/009643Eris Life sciences Pvt Ltd
进行中(未招募)
不适用
A Phase IV, multi-centre, randomized, open label study to investigate the efficacy and safety of Floradix® mit Eisen and ferro sanol® duodenal mite 50 mg in pregnant women with diagnosed iron deficiencyPregnant women with diagnosed iron deficiencyMedDRA version: 12.1Level: LLTClassification code 10022976Term: Iron deficiency anemia secondary to inadequate dietary iron intakeEUCTR2010-018940-15-DESALUS Haus GmbH & Co. KG
进行中(未招募)
1 期
A phase 4, randomized, open label multi-centre clinical study to evaluate efficacy of Isoprinosine® in female subjects with low-grade cervical dysplasia caused by HrHPV.EUCTR2017-004235-36-CZEwopharma AG166
已完成
4 期
A post licensure clinical trial to evaluate the safety and tolerability of BEâ??s Inactivated Japanese Encephalitis Vaccine in â?¥18 to â?¤49 year old adult subjects in a two dose schedule.CTRI/2012/08/002909Biological E Limited432
